CYTOR and head and neck squamous cell carcinoma: To assess the therapeutic value of targeting CYTOR in HNSCC, the HNSCC subcutaneous xenograft models were established and then administered with CYTOR antisense oligonucleotide (ASO) by intratumoral injection.